Echo Therapeutics Inc (NASDAQ:ECTE)

1.65
Delayed Data
As of Apr 17
 -0.17 / -9.34%
Today’s Change
0.39
Today|||52-Week Range
3.47
+22.22%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$18.4M

Company Description

Echo Therapeutics, Inc. is a transdermal medical device company with significant expertise in advanced skin permeation technology. The company is involved in developing Prelude SkinPrep System, which is a platform technology to allow painless skin permeation that would enable both needle-free drug delivery and analyte extraction; and Symphony CGM System, a non-invasive, wireless, and transdermal continuous glucose monitoring system for use in hospital critical care units and for patients with diabetes. It also engages in the development of specialty pharmaceuticals based on its proprietary AzoneTS transdermal drug reformulation technology. The company's drug candidate is Durhalieve, an AzoneTS formulation of triamcinolone acetonide for the treatment of corticosteroid-responsive dermatoses. Echo Therapeutics was founded on September 14, 2007 and is headquartered in Philadelphia, PA.

Contact Information

Echo Therapeutics, Inc.
8 Penn Center
Philadelphia Pennsylvania 19103
P:(215) 717-4100
Investor Relations:
(215) 717-4104

Employees

Shareholders

Other institutional7.27%
Mutual fund holders3.32%
Individual stakeholders19.01%

Top Executives

Scott Wayne HollanderPresident, Chief Executive Officer & Director
Thomas H. BishopVice President-Operations & Product Development
Alan Wayne SchoenbartChief Financial Officer & Secretary
Kenneth GarySenior Vice President-Research & Development
Mary McNamara-CullinaneVice President-Regulatory & Clinical Affairs

To view my watchlist

Not a member yet?

Sign up now for a free account